Vol 4 (June 2021): Precision Cancer Medicine

Editorial Commentary 
PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads
Bartłomiej Tomasik, Michał Bieńkowski, Jacek Jassem
Precision Cancer Medicine  
2021;
4:
19  
Editorial Commentary 
Lung cancer screening: think pink!
Monica Casiraghi, Lorenzo Spaggiari
Precision Cancer Medicine  
2021;
4:
18  
Case Report 
Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series
Fabrizio Citarella, Marco Russano, Alessandro Galletti, Giuseppina-Rita Di Fazio, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine  
2021;
4:
17  
Review Article 
ROS-1 NSCLC therapy resistance mechanism
Miguel García-Pardo, Antonio Calles
Precision Cancer Medicine  
2021;
4:
16  
Review Article 
Monitoring therapeutic response and resistance with liquid biopsy
Virginia Calvo, Atocha Romero, Mariano Provencio
Precision Cancer Medicine  
2021;
4:
15  
Review Article 
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Rossella Bruno, Greta Alì, Anello Marcello Poma, Gabriella Fontanini
Precision Cancer Medicine  
2021;
4:
14  
Review Article 
A narrative review of chemotherapy in advanced triple negative breast cancer
Maria L. Romero Lagunes, Rossanna C. Pezo
Precision Cancer Medicine  
2021;
4:
13  
Review Article 
Triple negative breast cancer: emerging light on the horizon—a narrative review
Umangjot K. Bharaj, Ana E. Lohmann, Phillip S. Blanchette
Precision Cancer Medicine  
2021;
4:
12  
Original Article 
The use of stereotactic body radiotherapy in pulmonary carcinoid tumors: a case series
Katharine Thomas, Chris Smith, Andrew Marsala, John Philip Boudreaux, Ramcharan Thiagarajan, Robert A. Ramirez
Precision Cancer Medicine  
2021;
4:
11